CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

AbelZeta reports 91.7% disease control rate in Phase I liver cancer trial of C-CAR031

By Public Technologies
  • AbelZeta announced updated Phase I results for C-CAR031, now AZD7003, in advanced liver cancer, previously presented at ESMO on October 26, 2026.
  • The trial in 36 heavily pretreated patients showed tumor shrinkage, an encouraging survival signal and a manageable safety profile.
  • Serious inflammatory reactions and lung disease occurred at the highest dose, though no dose-limiting toxicities were observed.
  • AstraZeneca holds sole worldwide development, manufacturing and commercialization rights following its January 2026 acquisition of remaining China rights.
  • AbelZeta remains eligible for milestone payments and royalties under existing agreements.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abelzeta Inc. published the original content used to generate this news brief on November 09, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk